TRIZIVIR (abacavir/lamivudine/zidovudine) is a three-drug combination formulation of human immunodeficiency virus (HIV-1) nucleoside analog reverse transcriptase inhibitors (NRTI). TRIZIVIR is indicated for the treatment of HIV-1 infection, in combination with other antiretroviral drugs.
Dosing & Administration
TRIZIVIR is indicated for the treatment of HIV infection in adults and pediatric patients weighing 40kg or more. The dose is one tablet by mouth twice a day. Since some components of TRIZIVIR require dose adjustments in patients with liver or kidney dysfunction, TRIZIVIR is not recommended for use in these patients.
Patients with a hypersensitivity to abacavir (a component of TRIZIVIR) should not take this drug.
The most common side effects of TRIZIVIR include headache, vomiting, nausea, and weakness or tiredness. Possible side effects associated with this drug include increased myocardial infarction risk, loss of body fat, and changes in the immune system.
Serious and fatal hypersensitivity reactions have occurred with products containing abacavir and are considered a multi-organ clinical syndrome. Patients who carry the HLA-B*5701 allele are at a higher risk.
Hematologic toxicity is associated with the use of zidovudine. These include neutropenia and anemia, both reduced blood cell disorders. These are more likely in advanced disease of HIV-1.
Myopathy has occurred with prolonged use of zidovudine. These involve muscle pain and muscle weakness as symptoms.
Lactic acidosis and severe hepatomegaly with steatosis have been reported with the use of all three components of TRIZIVIR. The build up of acid in the blood is serious and fatal cases have been reported.
Severe acute hepatitis B exacerbations have occurred in patients who are co-infected with hepatitis B virus (HBV) and HIV-1 and have stopped lamivudine.
TRIZIVIR is associated with a number of drug-drug interactions and prescribers should familiarize themselves with the list provided in the package insert.
Pregnancy & Lactation
A pregnancy registry is in place for women who take antiretroviral medicines during pregnancy. The purpose of this registry is to collect information about the health of the patient and the baby.
Patients should refrain from breastfeeding if having HIV-1 due to the risk of transmission to an HIV-1 negative baby and the development of viral resistance in HIV-1 positive infants. All three components of this drug are present in human milk. Effects of the drug on milk production are unknown.
There is no known treatment specific for TRIZIVIR overdose. Hemodialysis has been shown to remove only a negligible amount of some of the components of TRIZIVIR.
Reviews are only written by verified customers who have purchased this product.